Publicacións nas que colabora con Francisco Javier González Barcala (20)

2024

  1. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 23-32

  2. The discrepancy in bronchodilator response between ATS/ERS 2021 and 1991 criteria

    Respiratory Medicine, Vol. 226

2023

  1. Disposition of Work-Related Asthma in a Spanish Asthma Cohort: Comparison of Asthma Severity Between Employed and Retired Workers

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 11, pp. 3407-3413.e1

  2. Does asthma-bronchiectasis overlap syndrome (ABOS) really exist?

    Journal of Asthma, Vol. 60, Núm. 11, pp. 1935-1941

  3. Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 281-288

  4. Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 223-231

  5. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti–IL-5 Biologics: A Real-Life Study

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 1, pp. 37-44

  6. Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 294-296

  7. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps

    Clinical Reviews in Allergy and Immunology, Vol. 64, Núm. 2, pp. 179-192

  8. Reply to “Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies”

    Journal of Investigational Allergology and Clinical Immunology

  9. Serum exosome inflamma-miRs are surrogate biomarkers for asthma phenotype and severity

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 1, pp. 141-155

  10. The New ERS/ATS 2022 Bronchodilator Response Recommendation: Comparison With the Previous Version in an Asthma Cohort

    Archivos de Bronconeumologia, Vol. 59, Núm. 9, pp. 608-611

2022

  1. Anxiety and body mass index affect asthma control: data from a prospective Spanish cohort

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 3, pp. 863-866.e1

  2. How reliably can algorithms identify eosinophilic asthma phenotypes using non-invasive biomarkers?

    Clinical and Translational Allergy, Vol. 12, Núm. 8

  3. The polyhedric reality of the interaction between COVID-19, asthma and inhaled corticosteroids

    ERJ Open Research

  4. With the Torch in the Mist of the United Airway Disease: Atopic March and Other Arguments in the Search for Evidence

    Archivos de Bronconeumologia

  5. [Translated article] With the Torch in the Mist of the United Airway Disease: Atopic March and Other Arguments in the Search for Evidence

    Archivos de Bronconeumologia

2018

  1. Expansion of a CD26low effector th subset and reduction in circulating levels of sCD26 in stable allergic asthma in adults

    Journal of Investigational Allergology and Clinical Immunology, Vol. 28, Núm. 2, pp. 113-125

2017

  1. Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate-severe asthma

    BMJ Open Respiratory Research, Vol. 4, Núm. 1

2016

  1. Validation of the 'Test of the Adherence to Inhalers' (TAI) for Asthma and COPD Patients

    Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 29, Núm. 2, pp. 142-152